- http://www.sareptafarmaceutica.com.br/
- https://www.sareptatherapeutics.fr/fr
- https://sareptatherapeutics.de/de
- http://www.sareptatherapeutics.it/
- https://www.sareptatherapeutics.co.jp/ja
- https://www.sareptatherapeutics.ch/de
- https://www.sareptatherapeutics.ch/fr
- https://www.sareptatherapeutics.ch/en
- https://www.sareptatherapeutics.ch/it
- https://www.sareptatherapeutics.co.uk/
- https://www.sarepta.com/
- https://duchennegenetherapy.com/
- http://investorrelations.sarepta.com/
- http://investorrelations.sarepta.com/news-releases
- http://investorrelations.sarepta.com/events-and-presentations
- http://investorrelations.sarepta.com/corporate-governance
- http://investorrelations.sarepta.com/stock-information/stock-quote
- http://investorrelations.sarepta.com/sec-filings
- http://investorrelations.sarepta.com/financial-information/fundamentals/snapshot
- http://investorrelations.sarepta.com/analyst-coverage
- http://investorrelations.sarepta.com/document-request
- http://investorrelations.sarepta.com/faqs
- https://www.sarepta.com/our-technology
- http://www.duchennegenetherapy.com
- https://www.sarepta.com/our-product/sareptassist
- https://www.sarepta.com/pipeline/exon-skipping-duchenne
- https://www.sarepta.com/our-team/career-opportunities
- https://www.sarepta.com/company/strategic-partnerships
- https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-receives-complete-response-letter-us-food
- https://investorrelations.sarepta.com/events/event-details/sarepta-therapeutics-second-quarter-2019-earnings-call
- https://twitter.com/sarepta
- https://www.linkedin.com/company/sarepta-therapeutics
No hay comentarios:
Publicar un comentario